Vistagen Therapeutics, Inc.

VTGN

US92840H4002

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
4.37 ^USD	-2.46%		-2.89%	-14.98%

Apr. 25	Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	CI
Apr. 01	Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	CI

VistaGen Therapeutics, Inc. Terminates Employment of H. Ralph Snodgrass as President and Chief Scientific Officer

June 22, 2022 at 04:55 pm EDT

On and effective June 15, 2022, VistaGen Therapeutics, Inc. (the “Company”) terminated the employment of H. Ralph Snodgrass, Ph.D., who served as the Company's President and Chief Scientific Officer.

Latest news about Vistagen Therapeutics, Inc.

Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue	Apr. 25	CI
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2	Apr. 01	CI
Transcript : Vistagen Therapeutics, Inc., Q3 2024 Earnings Call, Feb 13, 2024	Feb. 13
Vistagen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 13	CI
Earnings Flash (VTGN) VISTAGEN Posts Q3 Revenue $411,400	Feb. 13	MT
Vistagen to Get Patent for Neuropathic Pain Treatment Candidate in Europe	Dec. 27	MT
Vistagen	Dec. 27	MT
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain	Dec. 27	CI
North American Morning Briefing : Futures Pause -2-	Dec. 08	DJ
Jefferies Upgrades VistaGen Therapeutics to Buy From Hold, Raises Price Target to $15 From $6	Dec. 07	MT
Stifel Starts VistaGen Therapeutics With Buy Rating, $12 Price Target	Nov. 14	MT
Transcript : Vistagen Therapeutics, Inc., Q2 2024 Earnings Call, Nov 09, 2023	Nov. 09
Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (VTGN) VISTAGEN Reports Q2 Revenue $277.7M	Nov. 09	MT
Vistagen Therapeutics, Inc. Appoints Joshua Prince as the Chief Operating Officer	23-10-26	CI
Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating	23-10-17	MT
Global markets live: Rio Tinto, Bank of America, J&J, Pfizer, Microsoft...	23-10-17
Rate hike fears return with a vengeance	23-10-17
Vistagen Therapeutics, Inc. Provides Details Regarding Development Plans for Fasedienol	23-10-02	CI
Vistagen Therapeutics Reports Positive Results From Study of Neuroactive Nasal Spray for Premenstrual Dysphoric Disorder	23-09-12	MT
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder	23-09-12	CI
Vistagen Therapeutics, Fuji Pharma Sign Exclusive Negotiation Deal for Japanese Market	23-09-05	MT
Vistagen and Fuji Pharma Co., Ltd. Enter Exclusive Negotiation Agreement for Potential License to Develop and Commercialize Vistagen?s Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan	23-09-05	CI
Vistagen Therapeutics Hires Alnylam's Cindy Anderson to Become Finance Chief	23-08-22	MT
Vistagen Appoints Cindy Anderson as Chief Financial Officer	23-08-22	CI

Chart Vistagen Therapeutics, Inc.

Duration

Period

More charts

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders. Its pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as low-dose nasal sprays, are designed with a rapid-onset mechanism of action that activates chemosensory neurons in the nasal cavity and can impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. PH94B is a synthetic investigational pherine from the androstane family.

Sector

Biotechnology & Medical Research

Calendar

2024-05-15 - RBC Capital Markets Global Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.37 USD

Average target price

13.25 USD

Spread / Average Target

+203.20%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VISTAGEN THERAPEUTICS, INC.	-14.98%	118M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs